The potential role of functional inhibition of T regulatory cells by anti-TGFβ antibody in photodynamic therapy of renal cancer

Pawel Mroz, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Photodynamic therapy (PDT) has been shown to be an effective locally ablative anti-cancer treatment that has the additional advantage of inducing tumor-directed immune response. We hypothesized that PDT could be combined with anti-transforming growth factor (TGF) beta antibody that does not significantly affect the population of cytotoxic T lymphocytes (CTL) but at the same time, has the potential to decrease the immunosuppressive effects of regulatory T-cells (Treg) mediated by TGF beta. This hypothesis was tested with aTGF-beta antibody combined with BPD-mediated PDT in a BALB/c renal cell carcinoma model. Evidence of positive benefits of the combination therapy over individual treatments alone was obtained.

Original languageEnglish (US)
Title of host publicationBiophotonics and Immune Responses VI
DOIs
StatePublished - Apr 14 2011
EventBiophotonics and Immune Responses VI - San Francisco, CA, United States
Duration: Jan 23 2011Jan 24 2011

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume7900
ISSN (Print)1605-7422

Conference

ConferenceBiophotonics and Immune Responses VI
CountryUnited States
CitySan Francisco, CA
Period1/23/111/24/11

Keywords

  • Anti-tumor immunity
  • Kidney cancer
  • Photodynamic therapy
  • Regulatory T-cells
  • Transforming growth factor beta

Fingerprint Dive into the research topics of 'The potential role of functional inhibition of T regulatory cells by anti-TGFβ antibody in photodynamic therapy of renal cancer'. Together they form a unique fingerprint.

Cite this